Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: Analysis of quantitative salivary scan

Thyroid

Volumn 18, Issue 3, 2008, Pages 325-331

  Kim, Seong Jang ^a   Choi, Hee Young ^a   Kim, In Ju ^a   Kim, Yong Ki ^a   Jun, Sungmin ^a   Nam, Hyun Yul ^a   Kim, Ju Sung ^b  

^a Pusan National University Hospital   (South Korea)

^b Silla University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; IODINE 131; ONDANSETRON; PERTECHNETIC ACID TC 99M;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL PROTECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PARENCHYMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND FUNCTION; SCINTIGRAPHY; THYROID CANCER; TIME TO MAXIMUM PLASMA CONCENTRATION; XEROSTOMIA;

ADULT; AGED; AMIFOSTINE; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; CYTOPROTECTION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RADIATION INJURIES; RADIATION-PROTECTIVE AGENTS; SALIVARY GLANDS; THYROID NEOPLASMS;

EID: 40949086393     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2007.0191     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ 2006 Cancer statistics, 2006. CA Cancer J Clin 56:106-130.
2. Haugen BR 2004 Patients with differentiated thyroid carcinoma benefit from radioiodine remnant ablation. J Clin Endocrinol Metab 89:3665-3667.
3. Sawka AM, Thephamongkhol K, Brouwers M, Thabane L, Browman G, Gerstein HC 2004 A systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 89:3668-3676.
4. Dai G, Levy O, Carrasco N 1996 Cloning and characterization of the thyroid iodide transporter. Nature 379:458-460.
5. - symporter (NIS); recent advances. J Bioenerg Biomembr 30:195-206.
6. Smanik PA, Liu Q, Furminger TL, Ryu K, Xing S, Mazzaferri EL, Jhiang SM 1996 Cloning of the human sodium iodide symporter. Biochem Biophys Res Commun 226:339-345.
7. Spitzweg C, Heufelder AE 1998 The sodium iodide symporter: its emerging relevance to clinical endocrinology. Eur J Endocrinol 138:3555-3558.
8. Chung JK 2002 Sodium iodide symporter: its role in nuclear medicine. J Nucl Med 43:1188-1200.
9. Spitzweg C, Joba W, Schriever K, Goellner JR, Morris JC, Heufelder AE 1999 Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands. J Clin Endocrinol Metab 84:4178-4184.
10. Alexander C, Bader JB, Schaefer A, Finke C, Kirsch CM 1998 Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. J Nucl Med 39:1551-1554.
11. Solans R, Bosch JA, Galofre P, Porta F, Roselló J, Selva-O'Callagan A, Vilardell M 2001 Salivary and lacrimal gland dysfunction (sicca syndrome) after radioiodine therapy. J Nucl Med 42:738-743.
12. Caglar M, Tuncel M, Alpar R 2002 Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med 27:767-771.
13. Cappizi RL 1999 The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 26:3-21.
14. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R 2000 Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18:3339-3345.
15. Buntzel J, Kuttner K, Frohlich D, Glatzel M 1998 Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Oncol 9:505-509.
16. Bennett CL, Lane D, Stinson T, Glatzel M, Buntzel I 2001 Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Invest 19:107-113.
17. Peters K, Mucke R, Hamann D, Ziegler PG, Fietkau R 1999 Supportive use of amifostine in patients with head and neck tumors undergoing radio-chemotherapy. Is it possible to limit the duration of the application of amifostine? Strahlenther Onkol 175:23-26.
18. Buentzel J, Micke O, Adamietz IA, Monnier A, Glatzel M, Alexander de Vries 2006 Intravenous amifostine during chemoradiotherapy for head and neck cancer: a randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64:684-691.
19. Bohuslavizki KH, Brenner W, Klutmann S, Hübner RH, Lassmann S, Feyerabend B, Lüttges J, Tinnemeyer S, Clausen M, Henze E 1998 Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med 39:1237-1242.
20. Bohuslavizki KH, Klutmann S, Brenner W, Mester J, Henze E, Clausen M 1998 Salivary gland protection by amifostine in high-dose radioiodine treatment: results of a double-blind placebo-controlled study. J Clin Oncol 16:3542-3549.
21. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S 2005 Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 46:261-266.
22. Aung W, Murata Y, Ishida R, Takahashi Y, Okada N, Shibuya H 2001 Study of quantitative oral radioactivity in salivary gland scintigraphy and determination of the clinical stage of Sjögren's syndrome. J Nucl Med 43:38-43.
23. Umehara I, Yamada I, Murata Y, Takahashi Y, Okada N, Shibuya H 1999 Quantitative evaluation of salivary gland scintigraphy in Sjogren's syndrome. J Nucl Med 40:64-69.
24. Nakamura J, Shaw LM, Brown DQ 1987 Hydrolysis of WR-2721 by mouse liver cell fractions. Radiat Res 109:143-152.
25. Mori T, Nikaido O, Sughara T 1984 Dephosphorylation of WR-2721 with mouse tissue homogenates. Int J Radiat Oncol Biol Phys 10:1529-1531.
26. Shaw LM, Bonner HS, Brown DQ 1994 Metabolic pathways of WR-2721 (Ethyol, amifostine) in BALB/c mouse. Drug Metab Disp 10:895-902.
27. Sigdestad CP, Treacy SH, Knapp LA, Grdina DJ 1987 The effect of 2-[aminopropylamino] ethanthiol (WR-1065) in radiation induced double strand damage and repair in V79 cells. Br J Cancer 55:477-482.
28. Meyn RE, Jenkins WT 1983 Variation in normal and tumor tissue sensitivity of mice to ionizing radiation-induced strand breaks in vivo. Cancer Res 43:5668-5673.
29. DeNeve WJ, Everett CK, Suminski JE, Valeriote FA 1988 Influence of WR-2721 on DNA-cross linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo. Cancer Res 48:6002-6005.
30. Treskes M, Nijtmans LG, Fichtinger-Schepman AM, van der Vijgh WJ 1992 Effects of modulating agent WR-2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 43:1013-1019.
31. Wasserman TH, Brizel DM, Henke M, Monnier A, Eschwege F, Sauer R, Strnad V 2005 Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head and neck cancer: 2 year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63:985-990.
32. Marina N, Chang KW, Malogolowkin M, London WB, Frazier AL, Womer RB, Rescorla F, Billmire DF, Davis MM, Perlman EJ, Giller R, Lauer SJ, Olson TA; Children's Oncology Group 2005 Amifostine does not protect against the ototoxicity of high dose cisplatin combined with etoposide and bleomycin in pediatric germ cell tumors; a Children's Oncology Group study. Cancer 104:841-847.
33. Movsas B, Scott C, Langer C, Werner-Wasik M, Nicolaou N, Komaki R, Machtay M, Smith C, Axelrod R, Sarna L, Wasserman T, Byhardt R 2005 Randomized trial of amifostine in locally advanced non small cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145-2154.